0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessSummary The novel combination of checkpoint inhibitors targeting the PD(L)1 pathway and anti-VEGFA therapy has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, biomarkers predictive of response to these therapies are still lacking, representing a major clinical challenge. See related articles by Zhang et al., p. 3499, and Zhu et al., p. 3537
Sarah Cappuyns, Josep M. Llovet (2022). Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs. Clinical Cancer Research, 28(16), pp. 3405-3407, DOI: 10.1158/1078-0432.ccr-22-1213.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Letter
Year
2022
Authors
2
Datasets
0
Total Files
0
Language
English
Journal
Clinical Cancer Research
DOI
10.1158/1078-0432.ccr-22-1213
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
